AU2002305816B2 - Sustained-release analgesic compounds - Google Patents

Sustained-release analgesic compounds Download PDF

Info

Publication number
AU2002305816B2
AU2002305816B2 AU2002305816A AU2002305816A AU2002305816B2 AU 2002305816 B2 AU2002305816 B2 AU 2002305816B2 AU 2002305816 A AU2002305816 A AU 2002305816A AU 2002305816 A AU2002305816 A AU 2002305816A AU 2002305816 B2 AU2002305816 B2 AU 2002305816B2
Authority
AU
Australia
Prior art keywords
analgesic
compound
moiety
opioid
steroidal anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002305816A
Other languages
English (en)
Other versions
AU2002305816A1 (en
Inventor
Paul Ashton
Grazyna Cynkowska
Tadeusz Cynkowski
Edmund Mickunas
Thomas J. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eyepoint Pharmaceuticals US Inc
Original Assignee
Psivida US Inc
Psivida Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psivida US Inc, Psivida Inc filed Critical Psivida US Inc
Publication of AU2002305816A1 publication Critical patent/AU2002305816A1/en
Application granted granted Critical
Publication of AU2002305816B2 publication Critical patent/AU2002305816B2/en
Assigned to PSIVIDA INC. reassignment PSIVIDA INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: CONTROL DELIVERY SYSTEMS
Assigned to PSIVIDA US INC. reassignment PSIVIDA US INC. Alteration of Name(s) in Register under S187 Assignors: PSIVIDA INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002305816A 2001-06-05 2002-06-05 Sustained-release analgesic compounds Ceased AU2002305816B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29555601P 2001-06-05 2001-06-05
US60/295,556 2001-06-05
PCT/US2002/017613 WO2002098427A2 (en) 2001-06-05 2002-06-05 Sustained-release analgesic compounds

Publications (2)

Publication Number Publication Date
AU2002305816A1 AU2002305816A1 (en) 2003-05-08
AU2002305816B2 true AU2002305816B2 (en) 2008-04-10

Family

ID=23138201

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002305816A Ceased AU2002305816B2 (en) 2001-06-05 2002-06-05 Sustained-release analgesic compounds

Country Status (15)

Country Link
US (1) US20030022876A1 (enExample)
EP (2) EP1399161B1 (enExample)
JP (2) JP4814486B2 (enExample)
KR (1) KR20040014544A (enExample)
CN (1) CN1514729B (enExample)
AR (1) AR034362A1 (enExample)
AT (1) ATE506064T1 (enExample)
AU (1) AU2002305816B2 (enExample)
BR (1) BR0210179A (enExample)
CA (1) CA2448665C (enExample)
DE (1) DE60239801D1 (enExample)
IL (1) IL158882A0 (enExample)
NZ (1) NZ529661A (enExample)
TW (1) TWI255186B (enExample)
WO (1) WO2002098427A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022853A1 (en) * 2001-04-26 2004-02-05 Control Delivery Systems, Inc. Polymer-based, sustained release drug delivery system
BR0209198A (pt) * 2001-04-26 2004-06-08 Control Delivery Sys Inc Métodos de sìntese de compostos contendo fenol
IN2014DN10834A (enExample) * 2001-09-17 2015-09-04 Psivida Inc
TW200500067A (en) * 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
MXPA05009757A (es) * 2003-03-13 2005-12-05 Controlled Chemicals Inc Conjugados de oxicodona con menor potencial de abuso y duracion de accion extendida.
US20050008695A1 (en) * 2003-05-21 2005-01-13 Control Delivery Systems, Inc. Compositions and methods for delivering a biologically active agent
TWI365880B (en) * 2004-03-30 2012-06-11 Euro Celtique Sa Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
US20060105941A1 (en) * 2004-11-12 2006-05-18 Allergan, Inc. Mixed antibiotic codrugs
US20090233841A1 (en) * 2005-01-05 2009-09-17 Regents Of The University Of Minnesota Analgesic conjugates
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
EP1829878A1 (de) 2006-03-02 2007-09-05 Universitätsklinikum Freiburg Neue Morphinverbindungen für pharmazeutische Zusammensetzungen
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US20090082314A1 (en) * 2007-06-29 2009-03-26 The Provost Fellows And Scholars Of The College Of The Targeting Prodrugs for the Treatment of Gastrointestinal Diseases
EP2067858A1 (en) 2007-12-07 2009-06-10 Universidad de Sevilla Animal models for neurodegenerative diseases
JP5757864B2 (ja) * 2008-05-20 2015-08-05 ニューロジェシックス， インコーポレイテッド 水溶性アセトアミノフェン類似体
AU2009249071A1 (en) 2008-05-20 2009-11-26 Neurogesx, Inc. Hepatoprotectant acetaminophen mutual prodrugs
AU2009249069A1 (en) 2008-05-20 2009-11-26 Neurogesx, Inc. Carbonate prodrugs and methods of using the same
MX347741B (es) * 2008-09-16 2017-05-10 Nektar Therapeutics Opioides pegilados con bajo potencial de abuso.
ES2589915T3 (es) 2008-10-08 2016-11-17 Xgene Pharmaceutical Inc Conjugados de GABA y métodos de utilización de los mismos
FR2939436B1 (fr) * 2008-12-10 2010-12-17 Sanofi Aventis Synthese de morphine-6-glucuronide ou de l'un de ses derives
US10849981B2 (en) 2009-07-02 2020-12-01 KemPham, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
CA2765836C (en) 2009-07-02 2014-10-07 Kempharm, Inc. Phenylethanoic acid, phenylpropanoic acid and phenylpropenoic acid conjugates and prodrugs of hydrocodone, methods of making and use thereof
UA102916C2 (uk) 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
IN2014DN03009A (enExample) 2011-10-26 2015-05-08 Kempharm Inc
US9295731B2 (en) * 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
KR101616998B1 (ko) * 2014-03-18 2016-04-29 전남대학교병원 오피오이드 진통제 및 p7c3를 포함하는 진통제 조성물
MX2017006520A (es) 2014-11-25 2017-08-09 Kempharm Inc * Acido benzoico, derivados de acido benzoico y conjugados de oxicodona de acido heteroaril carboxilico.
CA2969221C (en) 2014-12-02 2021-01-12 Travis Mickle Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods of making and use thereof
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
CN107033154B (zh) * 2016-02-02 2020-02-04 上海瀚迈生物医药科技有限公司 阿片受体拮抗剂缀合物及其应用
CN107778187A (zh) * 2016-08-26 2018-03-09 江苏恩华药业股份有限公司 一种地佐辛晶型a及其制备方法
EP3691618A1 (en) 2017-10-06 2020-08-12 Foundry Therapeutics, Inc. Implantable depots for the controlled release of therapeutic agents
CN116650732A (zh) 2018-01-08 2023-08-29 铸造疗法股份有限公司 经由治疗剂的控制递送用于治疗腔内癌症的装置、系统和方法
US12458589B2 (en) 2018-05-12 2025-11-04 Foundry Therapeutics, Inc. Implantable polymer depots for the controlled release of therapeutic agents
US10807995B2 (en) 2018-07-13 2020-10-20 Alkermes Pharma Ireland Limited Thienothiophene compounds for long-acting injectable compositions and related methods
US10799496B2 (en) 2018-07-13 2020-10-13 Alkermes Pharma Ireland Limited Naphthylenyl compounds for long-acting injectable compositions and related methods
EP3843710A1 (en) 2018-08-28 2021-07-07 Foundry Therapeutics, Inc. Polymer implants
CN109096191B (zh) * 2018-10-25 2022-03-08 西北工业大学 氟比洛芬美普他酚酯药用化合物及其制备方法
US10975099B2 (en) 2018-11-05 2021-04-13 Alkermes Pharma Ireland Limited Thiophene compounds for long-acting injectable compositions and related methods
US12509469B2 (en) * 2019-08-07 2025-12-30 Ripple Therapeutics Corporation Compositions and methods for the treatment of pain and dependence disorders
KR102665346B1 (ko) * 2022-01-04 2024-05-13 한국생명공학연구원 신규한 디클로로페녹시아세트산 유도체 및 이의 용도
CN117567477B (zh) * 2023-11-15 2026-05-26 宜昌人福药业有限责任公司 一种氢吗啡酮和二氢吗啡类药物低分子聚乙二醇化物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19607395A1 (de) * 1996-02-28 1997-09-04 Lohmann Therapie Syst Lts Morphin- und Diamorphinsalze anionischer nicht-narkotischer Analgetika vom Typ der substituierten Carbonsäuren, Verfahren zu deren Herstellung, deren Verwendung und die diese Salze enthaltenden pharmazeutischen Präparate
WO1998017673A1 (en) * 1996-10-21 1998-04-30 Cal International Limited Isosorbide aspirinate esters

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2999102A (en) * 1959-10-14 1961-09-05 Thomae Gmbh Dr K Bis-(steroid-21)-dicarboxylic acid esters
US3147183A (en) * 1962-04-16 1964-09-01 Boehringer Sohn Ingelheim Bis-(steroid-21)-dicarboxylic acid esters
FR2576213B1 (fr) * 1985-01-21 1989-02-24 Cortial Nouveau procede d'obtention de formes pharmaceutiques a liberation prolongee
JPH0232027A (ja) * 1988-07-19 1990-02-01 Rooman Kogyo:Kk 鎮痛剤
TW225536B (enExample) * 1990-08-23 1994-06-21 Ciba Geigy Ag
US5681964A (en) * 1990-10-23 1997-10-28 University Of Kentucky Research Foundation Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents
SE9003665D0 (sv) * 1990-11-16 1990-11-16 Kabivitrum Ab Morphine prodrugs
GB9116909D0 (en) * 1991-08-06 1991-09-18 Salford Ultrafine Chem & Res Morphine derivatives
EP0635019B1 (en) * 1992-04-06 1999-05-26 Biosite Diagnostics Inc. Opiate derivatives and protein and polypeptide opiate derivative conjugates and labels
JPH06271578A (ja) * 1993-03-15 1994-09-27 Natl Sci Council 鎮痛剤ナルブフィン前薬の誘導体
FR2708611B1 (fr) * 1993-07-29 1995-10-27 Meram Lab Sel de codéine de l'acide 2-(3-benzoylphényl)propionique, procédé d'obtention et compositions pharmaceutiques le contenant.
CA2167818A1 (en) * 1993-08-02 1995-02-09 Robert George Whittaker Therapeutic compound - fatty acid conjugates
US6051576A (en) * 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US5952499A (en) * 1995-01-16 1999-09-14 Commonwealth Scientific And Industrial Research Organisation Therapeutic compound-fatty acid conjugates
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US5840731A (en) * 1995-08-02 1998-11-24 Virginia Commonwealth University Pain-alleviating drug composition and method for alleviating pain
US6225321B1 (en) * 1997-06-05 2001-05-01 Oliver Yoa-Pu Hu Long analgesic acting nalbuphine polyester derivative and method of use
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US6306842B1 (en) * 2000-06-02 2001-10-23 Medinox, Inc. Protected forms of a combination of pharmacologically active agents and uses therefor
US20030118528A1 (en) * 2001-11-19 2003-06-26 Walters Kenneth A. Topical delivery of codrugs
WO2003061626A1 (en) * 2002-01-18 2003-07-31 Control Delivery Systems, Inc. Polymeric gel system for the controlled delivery of codrugs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19607395A1 (de) * 1996-02-28 1997-09-04 Lohmann Therapie Syst Lts Morphin- und Diamorphinsalze anionischer nicht-narkotischer Analgetika vom Typ der substituierten Carbonsäuren, Verfahren zu deren Herstellung, deren Verwendung und die diese Salze enthaltenden pharmazeutischen Präparate
WO1998017673A1 (en) * 1996-10-21 1998-04-30 Cal International Limited Isosorbide aspirinate esters

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Pharmacobiodynamics, Vol. 11, No. 9, 1988, pp 645-650 *

Also Published As

Publication number Publication date
BR0210179A (pt) 2004-04-27
CA2448665C (en) 2013-01-29
ATE506064T1 (de) 2011-05-15
WO2002098427A3 (en) 2003-02-20
JP2010155869A (ja) 2010-07-15
JP4814486B2 (ja) 2011-11-16
AR034362A1 (es) 2004-02-18
US20030022876A1 (en) 2003-01-30
CN1514729B (zh) 2012-09-05
NZ529661A (en) 2006-03-31
EP1709957A3 (en) 2007-02-14
EP1399161A2 (en) 2004-03-24
JP2004536811A (ja) 2004-12-09
EP1709957A2 (en) 2006-10-11
EP1399161B1 (en) 2011-04-20
TWI255186B (en) 2006-05-21
DE60239801D1 (de) 2011-06-01
IL158882A0 (en) 2004-05-12
WO2002098427A2 (en) 2002-12-12
CN1514729A (zh) 2004-07-21
CA2448665A1 (en) 2002-12-12
KR20040014544A (ko) 2004-02-14

Similar Documents

Publication Publication Date Title
CA2448665C (en) Sustained-release analgesic compounds
AU2002305816A1 (en) Sustained-release analgesic compounds
RU2505541C2 (ru) Конъюгаты гидрокодона с бензойной кислотой, производными бензойной кислоты и гетероарилкарбоновой кислотой, пролекарства, способы их получения и их применение
AU738743B2 (en) Antipruritic
KR101589846B1 (ko) 히드로모르폰의 벤조산, 벤조산 유도체 및 헤테로아릴 카르복실산 컨쥬게이트, 전구약물, 이의 제조 방법 및 용도
JP5657394B2 (ja) 疼痛の治療又は予防方法
CA2657355A1 (en) Tetrahydro isoquinoline derivatives, preparation methods and medicinal uses thereof
RU2683317C2 (ru) Конъюгаты оксикодона с бензойной кислотой, производными бензойной кислоты и гетероарилкарбоновой кислотой
EP1422230B1 (en) Novel ester derivatives of buprenorphine and their preparation processes, and long acting analgestic pharmaceutical compositions
JP2019077695A (ja) オキシモルホンの安息香酸、安息香酸誘導体及びヘテロアリールカルボン酸結合体、プロドラッグ、その製造法及び使用
WO2009121018A2 (en) Opioid-nornicotine codrugs for pain management
WO2011030205A1 (en) N-substituted benzenepropanamide or benzenepropenamide for use in the treatment of pain and inflammation
JPWO2006049248A1 (ja) 鎮痛剤
CN1107333A (zh) 那布扶林镇痛剂的长效前体药物及其制备方法
JP2004175706A (ja) 新規なブプレノルフィンのエステル誘導体及びそれらの調製方法、及び長時間効力持続性鎮痛薬剤組成物
JP7535569B2 (ja) オピオイドヘキサジエノエート及び選択的に置換されたヘキサジエノエートによってオピオイド受容体の結合を改善する組成物並びに方法
DK2991682T3 (en) PRODRUGS OF NAPROXEN AND DICLOFENAC
TWI226830B (en) Novel ester derivatives of buprenorphine and their preparation processes, and long acting analgesic pharmaceutical compositions
KR100704085B1 (ko) 신규한 부프레노핀 에스테르 유도체, 그의 제조 방법 및지속성 진통제 약학 조성물
JP3531170B6 (ja) 止痒剤
HK1115808B (en) Analgesic

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired